Literature DB >> 1449542

Comparative binding of etretinate and acitretin to plasma proteins and erythrocytes.

S Urien1, P Claudepierre, J Meyer, R Brandt, J P Tillement.   

Abstract

The interactions of etretinate and its main metabolite acitretin with human plasma proteins have been investigated in vitro by an erythrocyte partitioning technique that allows a quantitative estimation of the plasma and erythrocyte binding. Etretinate was extensively lipoprotein-bound (75% of plasma etretinate), with a binding constant for its main low density lipoprotein carrier of 40 x 10(6) M-1, accounting for 48% of the total plasma-bound drug. Acitretin was mainly albumin-bound (91% of plasma acitretin), with a binding constant of 0.7 x 10(6) M-1. The total plasma binding of both drugs was > 99% and, in blood, the fractions associated with erythrocytes were 14.5 and 8.1% of the total amount for etretinate and acitretin, respectively.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1449542     DOI: 10.1016/0006-2952(92)90087-y

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  4 in total

1.  Nicanartine improves in vitro resistance of lipoproteins to oxidation.

Authors:  E Dailly; S Urien; P Wülfroth; J P Tillement
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

2.  Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin.

Authors:  N Simon; E Dailly; O Combes; E Malaurie; M Lemaire; J P Tillement; S Urien
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

3.  Binding of a new multidrug resistance modulator, S9788, to human plasma proteins and erythrocytes.

Authors:  S Urien; P Nguyen; G Bastian; C Lucas; J P Tillement
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

4.  The antimalarial drug halofantrine is bound mainly to low and high density lipoproteins in human serum.

Authors:  B Cenni; J Meyer; R Brandt; B Betschart
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.